<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alosetron: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alosetron: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alosetron: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12232" href="/d/html/12232.html" rel="external">see "Alosetron: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708584"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious GI adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Infrequent but serious GI adverse reactions have been reported with the use of alosetron. These reactions, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and, rarely, blood transfusion, surgery, and death.</p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis. Patients should immediately report constipation or symptoms of ischemic colitis to their health care provider. Alosetron should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their health care provider if the constipation does not resolve after alosetron is discontinued. Patients with resolved constipation should resume alosetron only on the advice of their treating health care provider.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12824192"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lotronex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F131937"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Selective 5-HT<sub>3</sub> Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F131923"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f07dbc3b-505c-4037-a259-77d730b76d20">Irritable bowel syndrome with diarrhea, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with diarrhea, severe (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b>
<b>Safety: </b>Due to risk of serious adverse effects (eg, ischemic colitis), reserve for female patients with severe diarrhea-predominant irritable bowel syndrome symptoms for &gt;6 months who have had an inadequate response to conventional treatments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591','lexi-content-ref-35738725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591','lexi-content-ref-35738725'])">Ref</a></span>). Patient should be under the care of a clinician experienced with use of alosetron.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Standard dose: Oral:</b> Initial: 0.5 mg twice daily; if patient becomes constipated at 0.5 mg twice daily, discontinue therapy until constipation resolves. May restart at 0.5 mg once daily. If constipation recurs at 0.5 mg once daily, permanently discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29774051','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29774051','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage titration</i>
<b>:</b> If 0.5 mg twice daily is tolerated but response is inadequate after 4 weeks, may increase to 1 mg twice daily (maximum dose: 2 mg/day). If response is inadequate after 4 weeks at 1 mg twice-daily dosing, discontinue treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10468696','lexi-content-ref-29774051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10468696','lexi-content-ref-29774051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Low dose: Oral: </b>Due to safety concerns with standard dosing, some experts recommend initiating at 0.5 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Camilleri.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Camilleri.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage titration</i>
<b>:</b> After 4 weeks, increase dose only if needed to 0.5 mg twice daily; if response is inadequate after 4 weeks at 0.5 mg twice-daily dosing and patient is tolerating, may increase to 1 mg twice daily (maximum: 2 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Camilleri.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Camilleri.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50989991"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987348"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer's labeling; use with caution due to extensive metabolism and increased drug exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is contraindicated.</p></div>
<div class="block dot drugH1Div" id="F13254978"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Constipation:</b> Patients experiencing constipation with 0.5 mg twice daily should discontinue therapy until constipation resolves. Therapy may be reinitiated at 0.5 mg once daily. Discontinue immediately if constipation recurs at lower dose.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ischemic colitis:</b> Discontinue therapy immediately; do not restart</p></div>
<div class="block doe drugH1Div" id="F131924"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Dosage adjustment is not required; however, postmarketing experience suggests that elderly patients may be at greater risk for complications of constipation.</p></div>
<div class="block adr drugH1Div" id="F131888"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Constipation (9% to 29%; dose related)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachyarrhythmia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤1%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (2%), abdominal distress (≤7%), abdominal pain (5% to 7%; upper abdominal pain: 3%), active gastrointestinal lesion (≤1%), dyspepsia (≤1%), flatulence (3%), gastrointestinal distress (≤5%), gastrointestinal pain (≤5%), gastrointestinal spasm (≤1%), hemorrhoidal bleeding (3%), hemorrhoids (2% to 3%), ischemic colitis (≤1%), nausea (6%), viral gastroenteritis (≥3%), vomiting (≥3%), xerostomia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (≤1%), urinary tract infection (≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (≤1%), disruption of body temperature regulation (≤1%), drowsiness (≤1%), fatigue (≥3%), headache (≥3%), malaise (≤1%), pain (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (≤1%), muscle spasm (≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (≥3%), nasopharyngitis (≥3%), sinusitis (≥3%), upper respiratory tract infection (≥3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, extrasystoles, increased blood pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, allergic skin reaction, alopecia, dermatitis, eczema, folliculitis, nail disease, seborrheic dermatitis, skin infection, sweat gland disease</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Abnormal serum calcium, fluid volume disorder, HPA-axis suppression, hyperglycemia, hypoglycemia, phosphate imbalance, pituitary insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal tenderness, cholecystitis, colitis, decreased gastrointestinal motility, diverticulitis of the gastrointestinal tract, duodenitis, dysgeusia, gastric hyperacidity, gastritis, gastroenteritis, gastrointestinal obstruction, intestinal intussusception, intestinal obstruction, occult blood in stools, oral changes, proctitis, ulcerative colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, diuresis, gynecological bleeding, sexual disorder, urinary tract hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal erythrocytes, bruise, hematoma, hemoglobinopathy, hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal bilirubin levels, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (fungal infection, reproductive infection, and fungal reproductive infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Balance impairment, burning sensation, cognitive dysfunction, confusion, depressed mood, feeling hot, hypertonia, hypoesthesia, increased dream activity, memory impairment, sedated state, sensation of cold, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle rigidity, myalgia, ostealgia, skeletal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: ENT infection (including viral ENT infection), laryngitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Fecal impaction (Krause 2007), gastrointestinal perforation, gastrointestinal ulcer, mesenteric ischemia (small bowel)</p></div>
<div class="block coi drugH1Div" id="F131903"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Do not initiate in patients with constipation. History of chronic or severe constipation or sequelae from constipation; history of ischemic colitis, intestinal obstruction, stricture, toxic megacolon, GI perforation, adhesions, diverticulitis, Crohn disease, ulcerative colitis, history of severe hepatic impairment; history of impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; coadministration with fluvoxamine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F131885"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Constipation: <b>[US Boxed Warning]: Discontinue immediately in patients who develop constipation; infrequent but serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, or death have been reported</b> (obstruction, ileus, perforation [rare], impaction, toxic megacolon, secondary bowel ischemia). Constipation is a frequent, dose-related side effect; risk for complications from constipation may be increased in elderly, debilitated patients, or with concurrent use of other medications which decrease GI motility. Nonsevere constipation may be managed by temporarily interrupting therapy and decreasing the dose. Do not initiate in patients with constipation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ischemic colitis: <b>[US Boxed Warning]: Ischemic colitis has been reported during treatment</b> without warning. Discontinue and evaluate immediately in patients who experience rectal bleeding, bloody diarrhea, or a sudden worsening of abdominal pain, and do not restart therapy if ischemic colitis is diagnosed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in mild to moderate hepatic impairment (Child-Pugh class A or B) (extensively metabolized); contraindicated in severe impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients due to increased risk of complications from constipation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly due to increased risk of complications from constipation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[US Boxed Warning]: Only indicated for women with severe diarrhea-predominant irritable bowel syndrome who have not responded adequately to conventional therapy</b> who have chronic IBS symptoms (lasting ≥6 months) and are without anatomic or biochemical abnormalities of the GI tract. Severe diarrhea-predominant IBS includes at least one of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, and disability or restriction of daily activities due to IBS.</p></div>
<div class="block foc drugH1Div" id="F131897"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotronex: 0.5 mg, 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p></div>
<div class="block geq drugH1Div" id="F131882"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F131904"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Alosetron HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $29.45 - $34.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $58.90 - $68.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lotronex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $50.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $101.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F131900"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>May be administered with or without food.</p></div>
<div class="block meg drugH1Div" id="F7874546"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088624.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRlGq0nZWLaPCZbILtGGhucjg%3D%3D&amp;TOPIC_ID=9299" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088624.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F131899"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Irritable bowel syndrome, with diarrhea, severe:</b> Treatment of females with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who have chronic IBS symptoms (generally lasting 6 months or longer), have had anatomic or biochemical abnormalities of the GI tract excluded, and who have not responded adequately to conventional therapy.</p></div>
<div class="block mst drugH1Div" id="F131944"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lotronex may be confused with Lovenox, Protonix</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F131932"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F131890"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Alosetron. Management: Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors whenever possible. If combined use is necessary, monitor for increased alosetron effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Alosetron.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Alosetron.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Alosetron may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May decrease the metabolism of Alosetron.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Alosetron may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Alosetron.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of TraMADol.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F131917"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">When administered with food, absorption may be reduced by ~25%. Management: May administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F131905"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F131906"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if alosetron is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother; monitor infants for severe constipation or blood in stools.</p></div>
<div class="block pha drugH1Div" id="F131884"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alosetron is a potent and selective antagonist of a subtype of the serotonin 5-HT<sub>3</sub> receptor. 5-HT<sub>3</sub> receptors are ligand-gated ion channels extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels affect the regulation of visceral pain, colonic transit, and gastrointestinal secretions. In patients with irritable bowel syndrome, blockade of these channels may reduce pain, abdominal discomfort, urgency, and diarrhea.</p></div>
<div class="block phk drugH1Div" id="F131902"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 65 to 95 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 82% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensive hepatic metabolism via CYP2C9, 3A4, and 1A2. Thirteen metabolites have been detected in the urine. Biological activity of these metabolites in unknown. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Mean: 50% to 60% (range: 30% to &gt;90%); decreased with food (25%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (74%, 13% of total dose as unchanged drug); feces (11%, 1% of total dose as unchanged drug) </p></div>
<div class="block phksp drugH1Div" id="F51220147"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Exposure to alosetron is increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma levels are elevated by about 40% in patients 65 years and older.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Plasma concentrations are 30% to 50% lower and less variable in men</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58186282"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lotronex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alosetron | Lotronex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Camilleri.1">
<a name="Camilleri.1"></a>Camilleri M. Alosetron hydrochloride (Lotronex) for irritable bowel syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10468696">
<a name="10468696"></a>Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. <i>Aliment Pharmacol Ther</i>. 1999;13(9):1149-1159. doi:10.1046/j.1365-2036.1999.00610.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alosetron-drug-information/abstract-text/10468696/pubmed" id="10468696" target="_blank">10468696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15233703">
<a name="15233703"></a>Koch KM, Corrigan BW, Manzo J, et al. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. <i>Aliment Pharmacol Ther.</i> 2004;20(2):223-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alosetron-drug-information/abstract-text/15233703/pubmed" id="15233703" target="_blank">15233703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509028">
<a name="17509028"></a>Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. <i>Am J Gastroenterol</i>. 2007;102(8):1709-1719. doi:10.1111/j.1572-0241.2007.01282.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alosetron-drug-information/abstract-text/17509028/pubmed" id="17509028" target="_blank">17509028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29774051">
<a name="29774051"></a>Lacy BE, Nicandro JP, Chuang E, Earnest DL. Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. <i>Therap Adv Gastroenterol</i>. 2018;11:1756284818771674. doi:10.1177/1756284818771674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alosetron-drug-information/abstract-text/29774051/pubmed" id="29774051" target="_blank">29774051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alosetron-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738725">
<a name="35738725"></a>Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. <i>Gastroenterology</i>. 2022;163(1):137-151. doi:10.1053/j.gastro.2022.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alosetron-drug-information/abstract-text/35738725/pubmed" id="35738725" target="_blank">35738725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotronex.1">
<a name="Lotronex.1"></a>Lotronex (alosetron) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling</div>
</li></ol></div><div id="topicVersionRevision">Topic 9299 Version 201.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
